Bromisovalum
A brominated sedative and hypnotic agent that was used historically to treat anxiety and insomnia. It belongs to the bromide-containing compounds that were widely used before benzodiazepines became available. It is no longer in clinical use due to the risk of bromism with prolonged administration and the availability of safer alternatives.
Molekularmasse
223,0700 g/mol
LogP
1,10
TPSA
72,20 Ų
Lipinski-Regel der Fünf
Bestanden
Wirkmechanismus
Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …
2D-Struktur
Cite this structure
Embed this structure
SMILES
CC(C)C(Br)C(=O)NC(N)=O
InChI
InChI=1S/C6H11BrN2O2/c1-3(2)4(7)5(10)9-6(8)11/h3-4H,1-2H3,(H3,8,9,10,11)
Molecular Formula
C6H11BrN2O2
HBD / HBA
2 / 2
Rotierbare Bindungen
2
Schwere Atome
11
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
A brominated sedative and hypnotic agent that was used historically to treat anxiety and insomnia. It belongs to the bromide-containing compounds that were widely used before benzodiazepines became available. It is no longer in clinical use due to the risk of bromism with prolonged administration and the availability of safer alternatives.
Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.
Yes, Bromisovalum is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1515611. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 2447. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="bromisovalum"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/bromisovalum/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/bromisovalum/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/bromisovalum/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="bromisovalum"></drugfyi-drug>